IPO Gives Kyverna Cash To Maintain Lead In Autoimmune CAR-T Development
With Metagenomi And Telomir, US Offerings Total Seven
Kyverna CEO Peter Maag spoke with Scrip about the company’s five-year overnight success after its well-received IPO. Metagenomi and Telomir also went public in the US in smaller offerings.
